New hope for kids with colitis: budesonide pill trial aims for remission
NCT ID NCT04314375
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests whether budesonide extended-release tablets can safely help children aged 5 to 17 with mild to moderate ulcerative colitis achieve remission. About 70 participants will receive either a low dose, high dose, or placebo for 56 days. The goal is to reduce symptoms like rectal bleeding and frequent stools, with an endoscopic check to confirm improvement.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
budesonide extended-release tablets
What this could lead to
If successful, this could provide a treatment option for children with mild to moderate ulcerative colitis to achieve remission without needing stronger drugs.
What could go wrong
This is a phase 4 study with only 70 participants, so results may not apply to all children. Budesonide is a steroid and can have side effects like growth suppression or hormonal changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Bausch Health Site 003
RECRUITINGIndianapolis, Indiana, 46202, United States
-
Bausch Health Site 006
RECRUITINGThe Bronx, New York, 10467, United States
-
Bausch Health Site 008
RECRUITINGGarden Grove, California, 92845, United States
-
Bausch Health Site 010
RECRUITINGGreenville, North Carolina, 27834, United States